Sweden · Delayed Price · Currency is SEK Bonesupport Holding AB Earnings Call Transcripts
Fiscal Year 2026
-
Net sales grew 31% at constant exchange rates, driven by strong U.S. CERAMENT G performance and solid European growth. Adjusted operating margin improved to 26%, with robust cash flow and positive CMS reimbursement developments supporting future outlook.
Fiscal Year 2025
-
Q4 2025 saw 22% reported sales growth (36% at constant FX), driven by strong U.S. CERAMENT G adoption and expansion into trauma centers. Guidance for 2026 targets at least 35% constant FX growth, with upside from potential CERAMENT V approval.
-
Q3 2025 saw 24% sales growth (34% at constant currency), a 27% adjusted operating margin, and strong cash flow. U.S. CERAMENT G sales drove performance, with new clinical evidence supporting expansion into revision arthroplasty. Full-year guidance for 40%+ sales growth is reiterated.
-
Q2 2025 saw 29% reported sales growth (40% in constant currency), driven by CERAMENT G's strong U.S. performance and stable margins. Guidance for over 40% sales growth in constant currency is reaffirmed, with new product launches and favorable reimbursement changes expected to support future growth.
-
Q1 2025 saw 54% sales growth, driven by U.S. CERAMENT G adoption and strong cash flow. CMS proposed significant NTAP reimbursement, CERAMENT V was submitted to the FDA, and market share gains continued in Europe. Guidance for 2025 is sales growth above 40%.
Fiscal Year 2024
-
Q4 2024 saw 49% sales growth and record cash flow, led by CERAMENT G's US success and strong clinical evidence. Guidance for 2025 targets over 40% sales growth, with ongoing expansion into new markets and continued high gross margins.
-
Q3 2024 saw over 50% sales growth year-over-year, driven by CERAMENT G's rapid U.S. adoption and strong global performance. The SOLARIO study supports reduced systemic antibiotic use, and new market segments like open trauma and spinal fusion are expected to fuel future growth.
-
Q2 2024 saw 57% year-over-year sales growth to SEK 220 million, led by U.S. CERAMENT G uptake and strong market share gains. Gross margin remained high at 95.8%, and 2024 sales guidance was raised to over 50% growth in constant currency.